1. NF-κB Metabolic Enzyme/Protease Immunology/Inflammation
  2. Keap1-Nrf2 Reactive Oxygen Species
  3. Keap1-Nrf2-IN-14

Keap1-Nrf2-IN-14 (compound 20c) is a KEAP1-NRF2 inhibitor that effectively disrupts the KEAP1-NRF2 interaction (IC50=75 nM) with a Kd value of 24 nM for KEAP1. Keap1-Nrf2-IN-14 induces the expression of NRF2 target genes and enhances the downstream antioxidant and anti-inflammatory activities. Keap1-Nrf2-IN-14 can be used in the study of oxidative stress-related inflammation.

For research use only. We do not sell to patients.

Keap1-Nrf2-IN-14 Chemical Structure

Keap1-Nrf2-IN-14 Chemical Structure

CAS No. : 1928782-31-3

Size Price Stock Quantity
5 mg USD 360 Get quote 6 - 8 weeks 6 - 8 weeks 5 - 7 weeks
10 mg USD 600 Get quote 6 - 8 weeks 6 - 8 weeks 5 - 7 weeks
25 mg USD 1250 Get quote 6 - 8 weeks 6 - 8 weeks 5 - 7 weeks
50 mg USD 2000 Get quote 6 - 8 weeks 6 - 8 weeks 5 - 7 weeks
100 mg   Get quote  
200 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Keap1-Nrf2-IN-14

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Keap1-Nrf2-IN-14 (compound 20c) is a KEAP1-NRF2 inhibitor that effectively disrupts the KEAP1-NRF2 interaction (IC50=75 nM) with a Kd value of 24 nM for KEAP1. Keap1-Nrf2-IN-14 induces the expression of NRF2 target genes and enhances the downstream antioxidant and anti-inflammatory activities. Keap1-Nrf2-IN-14 can be used in the study of oxidative stress-related inflammation[1].

IC50 & Target[1]

KEAP1-NRF2

75 nM (IC50)

In Vitro

Keap1-Nrf2-IN-14 effectively activated NRF2-ARE regulated cytoprotective defense system in both concentration- and time- dependent manner in RAW264.7 cells[1].
Keap1-Nrf2-IN-14 (1, 10 µM; 12 h) enhanced the antioxidant capacity in macrophage RAW 264.7 cells[1].
Keap1-Nrf2-IN-14 (1, 10 µM; 12 h) attenuates LPS-induced production of inflammation factors in RAW 264.7 cells[1].
Keap1-Nrf2-IN-14 shows high metabolic stability (in co-incubation with rat liver microsomes with half-life of 10.5 h), and have no CYP inhibition on 1A2, 2C9, 2C19, 2D6 and 3A4 when at 10 µM.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: RAW264.7 cells (LPS-stimulated)
Concentration: 10 µM
Incubation Time: 12 h
Result: Significantly reduced ROS generation to nearly normal level.

Cell Viability Assay[1]

Cell Line: RAW264.7 cells (LPS-stimulated)
Concentration: 1, 10 µM
Incubation Time: 12 h
Result: Notably restored the SOD and GSH-Px levels.
Markedly attenuated the levels of the inflammatory factors IL-1b, IL-6, TNF-a and NO (induced by LPS) in a concentration-dependent manner, and when at 10 µM, almost reduced these cytokines to the basal level.

RT-PCR[1]

Cell Line: RAW264.7 cells
Concentration: 0.1, 1, 5, 10 µM
Incubation Time: 12 h
Result: Strongly increased the transcription of NRF2 regulated genes in RAW264.7 cells at a concentration-dependent manner.

Western Blot Analysis[1]

Cell Line: RAW264.7 cells
Concentration: 10 µM
Incubation Time: 1, 2, 4, 8, 16, 24 h
Result: Led to nuclear translocation of NRF2 began within 2 h, maximized at 8 h and subsequently declined after 16 h.
Induced NRF2, HO-1, NQO-1 and GCLM protein expression in a time- dependent manner.
In Vivo

Keap1-Nrf2-IN-14 (10 mg/kg; i.p.; single daily for 3 days) reduces the LPS-induced production of the proinflammatory factors in vivo[1].
Keap1-Nrf2-IN-14 (1 mg/kg; i.v.; single) shows half-life of 1.72 h in vivo[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C57BL/6 mice (18-22 g; LPS-induced inflammation model)[1].
Dosage: 10 mg/kg
Administration: Intraperitoneal injection; single daily for 3 days.
Result: Diminished LPS-induced inflammatory response in vivo.
Animal Model: Female C57BL/6 mice (18-22 g; LPS-induced inflammation model)[1].
Dosage: 1 mg/kg
Administration: Intravenous injection; single.
Result: Led to half-life of 1.72 h.
Molecular Weight

563.62

Formula

C30H29NO8S

CAS No.
SMILES

O=C(O)C(OC1=C2C=CC=CC2=C(N(CC(O)=O)S(=O)(C3=C(C)C=C(C)C=C3C)=O)C=C1)C4=CC=C(OC)C=C4

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Keap1-Nrf2-IN-14
Cat. No.:
HY-151362
Quantity:
MCE Japan Authorized Agent: